Core Viewpoint - Fuhong Hanlin (02696) shares have risen over 4% following the approval of two biosimilars, BILDYOS and BILPREVDA, by the UK Medicines and Healthcare products Regulatory Agency [1] Group 1: Company Developments - Fuhong Hanlin's stock price increased by 4.53%, reaching 64.6 HKD, with a trading volume of 79.4842 million HKD [1] - The UK regulatory approval covers all indications for the original drugs [1] - In 2022, Fuhong Hanlin granted Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [1] Group 2: Investment Activity - Boyu Capital Investment Management Limited purchased 262,500 shares and 80,000 shares of Fuhong Hanlin on November 6 and November 10, respectively, increasing their stake from 5.84% to 7% [1] - Earlier, on June 18, Boyu Capital had invested 21.2673 million HKD to raise their stake from 4.89% to 5.15%, surpassing the 5% threshold for reporting [1]
复宏汉霖现涨超4% 地舒单抗BILDYOS和BILPREVDA获英国批准上市